This Article Full Text Full Text (PDF) Figure 2-corrected Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Google Scholar Articles by Weitz, J. I. Articles by Samama, M. M. PubMed PubMed Citation Articles by Weitz, J. I. Articles by Samama, M. M.

New Antithrombotic Drugs^*

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)*

^* From the Henderson Research Center (Drs. Weitz and Hirsh), McMaster University, Hamilton, ON, Canada; and Hôtel-Dieu University Hospital (Dr. Samama), Paris, France.

Correspondence to: Jeffrey Weitz, MD, 711 Concession St, Hamilton, ON, L8V 1C3, Canada; e-mail: jweitz{at}thrombosis.hhscr.org

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.

Key Words: anticoagulants • antiplatelet drugs • antithrombotic drug • fibrinolytic agents